Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-24.59M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.27 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -872.99% |
| Return on Assets (Trailing 12 Months) | -239.04% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.59 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.59 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.67 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.43 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.31 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.56 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 14.24M |
| Free Float | 11.28M |
| Market Capitalization | $21.78M |
| Average Volume (Last 20 Days) | 0.45M |
| Beta (Past 60 Months) | 1.46 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 15.83% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |